New trials are investigating whether a diabetes drug already known for its cardiovascular benefits could become a powerful tool in slowing the progression of Alzheimer’s disease. Two large-scale studies, known as evoke and evoke+, are assessing the potential of oral semaglutide in people with early-stage Alzheimer’s, marking a major shift in how scientists approach treatment for this devastating condition. The findings were published in the journal Alzheimer’s Research & Therapy.
The trials, which include more than 3,600 participants across 40 countries, are focused on individuals aged between 55 and 85 who have either mild cognitive impairment or mild dementia due to Alzheimer’s, confirmed through biomarker testing. Participants receive either semaglutide or a placebo over a period of 156 weeks, with the primary goal of observing changes in cognitive and functional decline using the Clinical Dementia Rating–Sum of Boxes scoring system.
Semaglutide, a glucagon-like peptide-1 receptor agonist, is already widely prescribed for type 2 diabetes and obesity. It has an established safety profile and has demonstrated anti-inflammatory and vascular benefits. Preclinical evidence has suggested that the drug may also have neuroprotective effects, reducing neuroinflammation and improving blood–brain barrier integrity – both of which are thought to play a significant role in the development of Alzheimer’s.
What sets evoke and evoke+ apart is not only the scale of the trials but also the inclusion of participants with small vessel disease and those from diverse global backgrounds, potentially making the results more applicable to real-world clinical settings. The trials also allow for the continuation or initiation of existing approved Alzheimer’s treatments during the study, making the data particularly relevant to patients who are already being treated with drugs such as cholinesterase inhibitors or monoclonal antibodies.
In addition to monitoring cognitive scores, researchers are collecting blood and cerebrospinal fluid samples to examine changes in biomarkers associated with inflammation, synaptic function, and neuronal injury. These findings could offer new insight into how semaglutide works in the brain and whether it can genuinely alter the disease course.
Recruitment for both trials concluded in September 2023. The main study phase is due to end in 2025, with the final data collection wrapping up in 2026. While the trials are still ongoing, anticipation is growing that semaglutide could emerge as the first oral treatment to demonstrate disease-modifying potential in Alzheimer’s.
Although semaglutide may not target amyloid plaques directly, as newer intravenous therapies do, its broader impact on brain health could offer a safer and more convenient alternative for patients and carers alike. Should the results prove successful, they may redefine the landscape of Alzheimer’s treatment, with a drug that is already familiar to millions and supported by years of clinical data.
The medical community is watching closely. If these trials confirm even a modest slowing of cognitive decline, semaglutide could quickly become a cornerstone in the future of dementia care.
